180 related articles for article (PubMed ID: 30835046)
1. Immunological recovery in T-cell activation after sustained virologic response among HIV positive and HIV negative chronic Hepatitis C patients.
Emmanuel B; El-Kamary SS; Magder LS; Stafford KA; Charurat ME; Poonia B; Chairez C; McLaughlin M; Hadigan C; Masur H; Kottilil S
Hepatol Int; 2019 May; 13(3):270-276. PubMed ID: 30835046
[TBL] [Abstract][Full Text] [Related]
2. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?
Bischoff J; Mauss S; Cordes C; Lutz T; Scholten S; Moll A; Jäger H; Cornberg M; Manns MP; Baumgarten A; Rockstroh JK
HIV Med; 2018 Apr; 19(4):299-307. PubMed ID: 29368456
[TBL] [Abstract][Full Text] [Related]
3. Dominant enrichment of phenotypically activated CD38(+) HLA-DR(+) CD8(+) T cells, rather than CD38(+) HLA-DR(+) CD4(+) T cells, in HIV/HCV coinfected patients on antiretroviral therapy.
d'Ettorre G; Ceccarelli G; Serafino S; Giustini N; Cavallari EN; Bianchi L; Pavone P; Bellelli V; Turriziani O; Antonelli G; Stroffolini T; Vullo V
J Med Virol; 2016 Aug; 88(8):1347-56. PubMed ID: 26765625
[TBL] [Abstract][Full Text] [Related]
4. Direct-acting antiviral therapy enhances total CD4+ and CD8+ T-cells responses, but does not alter T-cells activation among HCV mono-infected, and HCV/HIV-1 co-infected patients.
Najafi Fard S; Schietroma I; Corano Scheri G; Giustini N; Serafino S; Cavallari EN; Pinacchio C; De Girolamo G; Ceccarelli G; Scagnolari C; Vullo V; d'Ettorre G
Clin Res Hepatol Gastroenterol; 2018 Sep; 42(4):319-329. PubMed ID: 29279268
[TBL] [Abstract][Full Text] [Related]
5. Peripheral PD-1
Romani S; Stafford K; Nelson A; Bagchi S; Kottilil S; Poonia B
Front Immunol; 2019; 10():1470. PubMed ID: 31316516
[TBL] [Abstract][Full Text] [Related]
6. IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T cell frequency and increases virus-specific T cell responses.
Han JW; Sung PS; Hong SH; Lee H; Koh JY; Lee H; White S; Maslow JN; Weiner DB; Park SH; Jeong M; Heo J; Ahn SH; Shin EC
J Hepatol; 2020 Jul; 73(1):72-83. PubMed ID: 32088322
[TBL] [Abstract][Full Text] [Related]
7. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death.
Chalouni M; Pol S; Sogni P; Fontaine H; Lacombe K; Marc-Lacombe J; Esterle L; Dorival C; Bourlière M; Bani-Sadr F; de Ledinghen V; Zucman D; Larrey D; Salmon D; Carrat F; Wittkop L;
J Hepatol; 2021 Jan; 74(1):37-47. PubMed ID: 32798585
[TBL] [Abstract][Full Text] [Related]
8. Benefit of direct-acting antiviral therapy for hepatitis C virus (HCV) in monoinfected and HIV-HCV-coinfected patients with mixed cryoglobulinaemia.
Miailhes P; Hartig-Lavie K; Virlogeux V; Pradat P; Diakite M; Uhres AC; Zoulim F; Sarda MN
Clin Microbiol Infect; 2018 Nov; 24(11):1215.e1-1215.e4. PubMed ID: 29870852
[TBL] [Abstract][Full Text] [Related]
9. Modifications of CD4 T cells, CD4/CD8 ratio and serum levels of soluble CD14 in HIV-HCV-coinfected patients after sustained HCV response induced by direct-acting antiviral agents: influence of liver cirrhosis.
Girón-Ortega JA; Márquez-Coello M; Gutiérrez-Saborido D; Arizcorreta A; Cuesta-Sancho S; Girón-González JA
Eur J Clin Microbiol Infect Dis; 2021 Sep; 40(9):1863-1871. PubMed ID: 33822285
[TBL] [Abstract][Full Text] [Related]
10. Predictive factors of hepatitis C virus eradication after interferon-free therapy in HIV coinfection.
Domínguez-Domínguez L; Bisbal O; Matarranz M; Lagarde M; Pinar Ó; Hernando A; Lumbreras C; Rubio R; Pulido F
Eur J Clin Microbiol Infect Dis; 2019 Apr; 38(4):725-734. PubMed ID: 30687869
[TBL] [Abstract][Full Text] [Related]
11. HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study.
Neukam K; Morano-Amado LE; Rivero-Juárez A; Mancebo M; Granados R; Téllez F; Collado A; Ríos MJ; de Los Santos-Gil I; Reus-Bañuls S; Vera-Méndez F; Geijo-Martínez P; Montero-Alonso M; Suárez-Santamaría M; Pineda JA
HIV Clin Trials; 2017 May; 18(3):126-134. PubMed ID: 28599618
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virologic response in hepatitis B and C coinfected persons treated with directly acting antiviral agents: Results from ERCHIVES.
Butt AA; Yan P; Aslam S; Sherman KE; Siraj D; Safdar N; Hameed B
Int J Infect Dis; 2020 Mar; 92():184-188. PubMed ID: 31978574
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal Assessment of Multiple Immunological and Inflammatory Parameters during Successful DAA Therapy in HCV Monoinfected and HIV/HCV Coinfected Subjects.
Zuccalà P; Latronico T; Marocco R; Savinelli S; Vita S; Mengoni F; Tieghi T; Borgo C; Kertusha B; Carraro A; D'Ettorre G; Vullo V; Mastroianni CM; Liuzzi GM; Lichtner M
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233234
[TBL] [Abstract][Full Text] [Related]
14. HCV-specific T-cell responses in HIV/hepatitis C virus-coinfected patients on highly active antiretroviral therapy are comparable to those observed in hepatitis C virus-monoinfected individuals.
Rallón NI; Soriano V; Restrepo C; García-Samaniego J; Labarga P; López M; Peris A; González-Lahoz J; Benito JM
J Acquir Immune Defic Syndr; 2011 May; 57(1):1-8. PubMed ID: 21786458
[TBL] [Abstract][Full Text] [Related]
15. The impact of DAA-mediated HCV eradication on CD4
Bandera A; Lorenzini P; Taramasso L; Cozzi-Lepri A; Lapadula G; Mussini C; Saracino A; Ceccherini-Silberstein F; Puoti M; Quiros-Roldan E; Montagnani F; Antinori A; d'Arminio Monforte A; Gori A;
J Viral Hepat; 2021 May; 28(5):779-786. PubMed ID: 33600068
[TBL] [Abstract][Full Text] [Related]
16. Clinical Characteristics and Treatment Outcomes of Patients with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection: Experience at a Single Center in Korea.
Lim DH; Jeong JY; Nam S; Choi J; Kwon HC; Yoon YB; Kim Y; Chin B
J Korean Med Sci; 2021 Nov; 36(46):e308. PubMed ID: 34845874
[TBL] [Abstract][Full Text] [Related]
17. Metabolic Changes in Chronic Hepatitis C Patients Who Carry IFNL4-ΔG and Achieve Sustained Virologic Response With Direct-Acting Antiviral Therapy.
Emmanuel B; El-Kamary SS; Magder LS; Stafford KA; Charurat ME; Chairez C; McLaughlin M; Hadigan C; Prokunina-Olsson L; O'Brien TR; Masur H; Kottilil S
J Infect Dis; 2020 Jan; 221(1):102-109. PubMed ID: 31504644
[TBL] [Abstract][Full Text] [Related]
18. Mild profile improvement of immune biomarkers in HIV/HCV-coinfected patients who removed hepatitis C after HCV treatment: A prospective study.
Garcia-Broncano P; Medrano LM; Berenguer J; Brochado-Kith O; González-García J; Jiménez-Sousa MÁ; Quereda C; Sanz J; Téllez MJ; Díaz L; JIménez JL; Resino S;
J Infect; 2020 Jan; 80(1):99-110. PubMed ID: 31585189
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the Hepatitis C Continua of Care Between Hepatitis C Virus/HIV Coinfected and Hepatitis C Virus Mono-Infected Patients in Two Treatment Eras During 2008-2015.
Roberson JL; Lagasca AM; Kan VL
AIDS Res Hum Retroviruses; 2018 Feb; 34(2):148-155. PubMed ID: 28974107
[TBL] [Abstract][Full Text] [Related]
20. Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis.
Corma-Gómez A; Macías J; Lacalle-Remigio JR; Téllez F; Morano L; Rivero A; Serrano M; Ríos MJ; Vera-Méndez FJ; Alados JC; Real LM; Palacios R; Santos IL; Imatz A; Pineda JA;
Clin Infect Dis; 2021 Oct; 73(7):e2109-e2116. PubMed ID: 32766891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]